Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City (COVIDGHPSJCite)

March 6, 2023 updated by: Groupe Hospitalier Paris Saint Joseph

The ongoing Coronavirus (Covid-19) pandemic is causing a major global health crisis and is shaking up hospital organizations. To date, the recognized risk factors for severe forms of Covid-19 infection are elderly patients (> 70 years), obese patients, patients with chronic renal or respiratory pathologies, cardiovascular history (stroke or coronary artery disease), chronic respiratory conditions, high blood pressure, diabetes, and cancer. Covid-19 is manifested by a risk of acute respiratory distress syndrome requiring management by invasive ventilation. The lethality of this infection is around 4% in the current data.

Drastic precautionary measures for the transmission of the virus, as well as the provision of critical care beds by canceling any scheduled non-urgent intervention or consultation, have shaken up the hospital organization.

In this context, it is essential to have forward-looking data in real time to adjust the care offer and better understand the impact of Covid-19 on the patient populations treated.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

3767

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Le Plessis-Robinson, France, 92350
        • Hôpital Marie Lannelongue
      • Paris, France, 75014
        • AURA Paris Plaisance
      • Paris, France, 75014
        • Groupe Hospitalier Paris Saint-Joseph
      • Paris, France, 75014
        • Fondation Sainte-Marie
      • Paris, France, 75014
        • Hôpital Bellan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patientwith symptoms compatible with infection by Covid-19 treated at the GHPSJ or in one of the establishments in the Paris Plaisance hospital city.

Description

Inclusion Criteria:

- Patient (of all ages) with symptoms compatible with infection by Covid-19 treated at the GHPSJ or in one of the establishments in the Paris Plaisance hospital city.

Exclusion Criteria:

  • Asymptomatic patient
  • Patient objecting to the use of their data

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical consequences of a Covid-19 infection in the care population
Time Frame: Year 2
This outcome measures the clinical consequences of a Covid-19 infection in the care population.
Year 2

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Risk factors at M6
Time Frame: Month 6
This outcome evaluates the risk factors of COVID-19 at month 6
Month 6
Risk factors at year 1
Time Frame: Year 1
This outcome evaluates the risk factors of COVID-19.
Year 1
Risk factors at year 2
Time Frame: Year 2
This outcome evaluates the risk factors of COVID-19.
Year 2
Impact of hospital reorganization on medical care at M6
Time Frame: Month 6
This outcome evaluates the impact of hospital reorganization on medical care at month 6.
Month 6
Impact of hospital reorganization on medical care at Year 1
Time Frame: Year 1
This outcome evaluates the impact of hospital reorganization on medical care at year 1.
Year 1
Impact of hospital reorganization on medical care at Year 2
Time Frame: Year 2
This outcome evaluates the impact of hospital reorganization on medical care at year 2.
Year 2

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Groupe Hospitalier Paris Saint Joseph

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2020

Primary Completion (Actual)

June 30, 2022

Study Completion (Actual)

March 6, 2023

Study Registration Dates

First Submitted

April 26, 2020

First Submitted That Met QC Criteria

April 26, 2020

First Posted (Actual)

April 28, 2020

Study Record Updates

Last Update Posted (Estimate)

March 7, 2023

Last Update Submitted That Met QC Criteria

March 6, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • Cohorte COVID GHPSJ CiteH

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe